|
Stories from the dialysis comunity across the globe.
|
|
New England Journal of Medicine Publishes Case Reports on the ... - Earthtimes (press release) |
 |
 |
|
Approximately 70% of patients with the most common mutation experience chronic renal insufficiency, chronic dialysis, or death by one year after the first ... read more |
|
|
Pas de progrès thérapeutiques en 2008 - Le Figaro |
|
|
|
... (firme Eumedica), un thrombolytique qui peut être utilisé désormais pour la désobstruction de cathéters veineux centraux ou de dialyse thrombosés. ... read more |
|
PRESENTAN TRATAMIENTO PARA PACIENTES DIABETICOS EN DIALISIS - Terra Argentina |
|
|
|
Especialistas presentaron hoy un tratamiento para pacientes diabéticos en diálisis que ayuda a eliminar líquidos, pudiendo controlar la cantidad de azúcar ... read more |
|
|
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® (eculizumab) in Patients ... (Business Wire via Yahoo! Finance) |
|
|
|
CHESHIRE, Conn.----Two separate case reports published today in the New England Journal of Medicine examine the investigational use of Soliris ® , a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. , in patients with a rare and severe inflammatory disease called atypical Hemolytic Uremic Syndrome . read more |
|
From arginine methylation to ADMA: A novel mechanism with ... - 7thSpace Interactive (press release) |
|
|
|
It has recently been shown to be dysregulated in chronic renal, vascular, and pulmonary diseases, and metabolic products originating from protein arginine ... read more |
|
|
|
|
<< Start < Prev 3881 3882 3883 3884 3885 3886 3887 3888 3889 3890 Next > End >>
|
|
Page 3887 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
